UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
or

Atossa Therapeutics Inc (ATOS)

Atossa Therapeutics Inc (ATOS)
0.6100 -0.0100 (-1.61%) 04/16/25 [NASDAQ]
0.6123 x 2 0.6188 x 17
Realtime by (Cboe BZX)
0.6123 x 2 0.6188 x 17
Realtime 0.6050 unch (-) 16:02 ET
Quote Overview for Wed, Apr 16th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
0.6000
Day High
0.6200
Open 0.6200
Previous Close 0.6200 0.6200
Volume 596,086 596,086
Avg Vol 694,959 694,959
Stochastic %K 39.52% 39.52%
Weighted Alpha -62.64 -62.64
5-Day Change -0.0188 (-3.03%) -0.0188 (-3.03%)
52-Week Range 0.5526 - 1.8100 0.5526 - 1.8100
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 80,512
  • Shares Outstanding, K 129,170
  • Annual Sales, $ 0 K
  • Annual Income, $ -25,500 K
  • EBIT $ -28 M
  • EBITDA $ -28 M
  • 60-Month Beta 1.46
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.12
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.20
  • Most Recent Earnings $-0.05 on 03/25/25
  • Next Earnings Date 05/12/25 [--]
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical Instruments

Options Overview Details

View History
  • Implied Volatility 339.31% ( +149.79%)
  • Historical Volatility 68.74%
  • IV Percentile 98%
  • IV Rank 76.72%
  • IV High 432.10% on 04/10/25
  • IV Low 33.52% on 09/10/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 21
  • Volume Avg (30-Day) 112
  • Put/Call OI Ratio 0.07
  • Today's Open Interest 13,967
  • Open Int (30-Day) 13,916

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.05
  • Number of Estimates 2
  • High Estimate -0.05
  • Low Estimate -0.06
  • Prior Year -0.05
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.5526 +8.81%
on 04/07/25
Period Open: 0.7197
0.7700 -21.91%
on 03/25/25
-0.1184 (-16.45%)
since 03/14/25
3-Month
0.5526 +8.81%
on 04/07/25
Period Open: 0.8466
0.9772 -38.47%
on 01/22/25
-0.2453 (-28.97%)
since 01/16/25
52-Week
0.5526 +8.81%
on 04/07/25
Period Open: 1.5400
1.8100 -66.78%
on 05/08/24
-0.9387 (-60.95%)
since 04/16/24

Most Recent Stories

More News
Atossa Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate Update

ATOS : 0.6050 (-2.94%)
Atossa Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results

ATOS : 0.6050 (-2.94%)
Atossa Therapeutics Announces Plans to Pursue Metastatic Breast Cancer Indication for (Z)-Endoxifen and Continued Engagement with FDA on Additional Indications

ATOS : 0.6050 (-2.94%)
Atossa Therapeutics Congratulates Board Director Dr. Tessa Cigler and Weill Cornell Medicine on CDC Grant to Enhance Breast Cancer Care

ATOS : 0.6050 (-2.94%)
Atossa Therapeutics Responds to PTAB Ruling on U.S. Patent No. 11,572,334 and Announces the Issuance of U.S. Patent No. 12,201,591

ATOS : 0.6050 (-2.94%)
Atossa Therapeutics Issues Letter to Shareholders Highlighting 2024 Accomplishments and Outlook for 2025

ATOS : 0.6050 (-2.94%)
Atossa Therapeutics Applauds U.S. Surgeon General’s Advisory Highlighting Alcohol as a Leading Preventable Cause of Breast Cancer

ATOS : 0.6050 (-2.94%)
TCMD Stock Rises 20% in Three Months: Should You Buy, Hold or Sell?

Tactile Systems Technology TCMD, a leader in innovative therapies for chronic conditions, has demonstrated consistent year-over-year revenue growth over the past three quarters. The company reported revenues...

TCMD : 13.35 (unch)
ATOS : 0.6050 (-2.94%)
TMDX : 85.38 (-2.06%)
Atossa Therapeutics Announces Discovery of Synergistic Compounds for (Z)-Endoxifen in Breast Cancer Treatment

Atossa Therapeutics announced data on new compounds potentially effective in combination with (Z)-endoxifen for breast cancer treatment.Quiver AI SummaryAtossa Therapeutics, Inc. announced the discovery...

ATOS : 0.6050 (-2.94%)
Atossa Therapeutics to Present Poster Describing the Discovery of Molecules Synergistic with (Z)-endoxifen for the Treatment of Breast Cancer at the 2024 San Antonio Breast Cancer Symposium

ATOS : 0.6050 (-2.94%)

Business Summary

Atossa Genetics Inc. is a healthcare company focused on the development and marketing of cellular and molecular diagnostic risk assessment products for breast cancer. The Company's diagnostic tests consist of medical devices which can collect fluid samples from the breast milk ducts. It is also conducting...

See More

Key Turning Points

3rd Resistance Point 0.6865
2nd Resistance Point 0.6686
1st Resistance Point 0.6459
Last Price 0.6050
1st Support Level 0.6053
2nd Support Level 0.5874
3rd Support Level 0.5647

See More

52-Week High 1.8100
Fibonacci 61.8% 1.3297
Fibonacci 50% 1.1813
Fibonacci 38.2% 1.0329
Last Price 0.6050
52-Week Low 0.5526

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Unlock High-Probability Trade Setups: Master Fractals & Time Frames Like a Pro